Filling the need for trusted information on national health issues…

Trending on kff Ebola Marketplaces Enrollment

  • your selections
Clear Search

Filter Results

date

Topics

Tags

Content Type

  • results
  • state & global data
  • slides
The Henry J. Kaiser Family Foundation

Medicare Restructuring: The FEHBP Model A Summary – Report

Medicare Restructuring: The FEHBP ModelExecutive SummaryAs policymakers consider measures to assure the long-range solvency of Medicare, one option that has received increasing attention is a “premium support” system. Under such a system beneficiaries would choose between the original Medicare fee-for-service program and a variety of competing health plans. They would…

Report Read More
The Henry J. Kaiser Family Foundation

Medicare: Options for Reform, A Public Dialogue on Health Care: The Future of Medicare – (Spanish)

Medicare: Options for Reform, A Public Dialogue on Health Care: The Future of Medicare – (Spanish)Report: Medicare: Opciones para la reforma

Report Read More
The Henry J. Kaiser Family Foundation

Medicare/Medicaid Dual Eligibles: Fiscal and Social Responsibilities for Vulnerable Populations

Report: Medicare/Medicaid Dual Eligibles: Fiscal And Social Responsibility For Vulnerable Populations

Report Read More
The Henry J. Kaiser Family Foundation

Out-of-Pocket Cost-Sharing Obligations for Low-Income Medicare Beneficiaries Under the House and Senate Prescription Drug Bills

This issue paper provides information on the out-of-pocket expenses for prescription drugs that low-income individuals would face under the Senate versus the House Medicare prescription drug benefit legislation. Issue Paper (.pdf)

Issue Brief Read More
The Henry J. Kaiser Family Foundation

Prescription Drug Coverage for Medicare Beneficiaries: A Summary of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003

This document, prepared by Health Policy Alternatives, Inc., provides a detailed summary of the prescription drug provisions of the Medicare legislation (P.L. 108-173) signed by the President on December 8, 2003.Report (.pdf)

Report Read More
The Henry J. Kaiser Family Foundation

Selected Findings on the New Medicare Rx Drug Law – Chartpack

Selected Survey Findings on the New Medicare Rx Drug Law – ChartpackSeniors are confused about the Medicare prescription drug law. Below is a series of chart illustrating selected findings from the January/February 2004 Kaiser Health Poll Report survey. The findings show that while about two-thirds of seniors report following the…

Poll Finding Read More
The Henry J. Kaiser Family Foundation

The New Medicare Drug Benefit:  Potential Effects of Pharmacy Management Tools on Access to Medications

The New Medicare Drug Benefit: Potential Effects of Pharmacy Management Tools on Access to MedicationsThis report describes the pharmacy benefit management tools that will be available to private plans administering the new Medicare drug benefit, including formularies, the definition of categories and classes, and cost sharing requirements. The authors conclude…

Issue Brief Read More
The Henry J. Kaiser Family Foundation

Selected Findings on Knowledge and Understanding of the New Medicare Rx Drug Program — May/June 2004 Kaiser Health Poll Report Survey

Topline findings from the May/June 2004 Kaiser Health Poll Report survey, including knowledge and opinions about the new Medicare prescription drug law.Survey Toplines (.pdf)

Poll Finding Read More
The Henry J. Kaiser Family Foundation

Grievance and Appeals Procedures: An Analysis of the MMA and Proposed Regulations

This paper, by Sara Rosenbaum, J.D., Director of the Center for Health Services Research and Policy at George Washington University, examines the procedures for resolving beneficiaries' grievances and appeals under the new Medicare drug benefit. It is one in a series commissioned by the Kaiser Family Foundation that analyzes issues…

Issue Brief Read More
The Henry J. Kaiser Family Foundation

Marketing and Privacy Issues: An Analysis of the MMA and Proposed Regulations

This paper, by Joy Pritts of the Health Policy Institute at Georgetown University, looks at issues related to drug plan marketing activities and privacy under the MMA.Issue Brief (.pdf)

Issue Brief Read More